Sex-specific associations of serum prolactin concentrations with cardiac remodeling: Longitudinal results from the Study of Health Pomerania (SHIP)

Atherosclerosis

Volumn 221, Issue 2, 2012, Pages 570-576

  Haring, Robin ^a   Völzke, Henry ^a   Vasan, Ramachandran S ^b,c   Felix, Stephan B ^a   Nauck, Matthias ^a   Dörr, Marcus ^a   Wallaschofski, Henri ^a  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Cardiac remodeling; Hypertrophy; Left ventricular mass; Population based cohort; Prolactin

Indexed keywords

PROLACTIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GEOMETRY; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; LONGITUDINAL STUDY; M MODE ECHOCARDIOGRAPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RISK FACTOR; SEX DIFFERENCE; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

AGED; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; GERMANY; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; INCIDENCE; LINEAR MODELS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROLACTIN; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; TIME FACTORS; VENTRICULAR REMODELING;

EID: 84858705507     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.01.017     Document Type: Article

References (46)

1. Cheng S., Xanthakis V., Sullivan L.M., et al. Correlates of echocardiographic indices of cardiac remodeling over the adult life course: longitudinal observations from the Framingham Heart Study. Circulation 2010, 122:570-578.
2. Gardin J.M., McClelland R., Kitzman D., et al. M-mode echocardiographic predictors of six- to seven-year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort (the Cardiovascular Health Study). Am J Cardiol 2001, 87:1051-1057.
3. de Simone G., Gottdiener J.S., Chinali M., Maurer M.S. Left ventricular mass predicts heart failure not related to previous myocardial infarction: the Cardiovascular Health Study. Eur Heart J 2008, 29:741-747.
4. Aurigemma G.P., Gottdiener J.S., Shemanski L., Gardin J., Kitzman D. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the cardiovascular health study. J Am Coll Cardiol 2001, 37:1042-1048.
5. Drazner M.H., Rame J.E., Marino E.K., et al. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. J Am Coll Cardiol 2004, 43:2207-2215.
6. Kardys I., Deckers J.W., Stricker B.H., Vletter W.B., Hofman A., Witteman J.C. Echocardiographic parameters and all-cause mortality: the Rotterdam Study. Int J Cardiol 2009, 133:198-204.
7. Lieb W., Larson M.G., Benjamin E.J., et al. Multimarker approach to evaluate correlates of vascular stiffness: the Framingham Heart Study. Circulation 2009, 119:37-43.
8. Cheng S., Vasan R.S. Advances in the epidemiology of heart failure and left ventricular remodeling. Circulation 2011, 124:e516-e519.
9. Ben-Jonathan N., Hugo E.R., Brandebourg T.D., LaPensee C.R. Focus on prolactin as a metabolic hormone. Trends Endocrinol Metab 2006, 17:110-116.
10. Dorshkind K., Horseman N.D. The roles of prolactin, growth hormone, insulin-like growth factor-I, and thyroid hormones in lymphocyte development and function: insights from genetic models of hormone and hormone receptor deficiency. Endocr Rev 2000, 21:292-312.
11. Bole-Feysot C., Goffin V., Edery M., Binart N., Kelly P.A. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 1998, 19:225-268.
12. Serri O., Li L., Mamputu J.C., Beauchamp M.C., Maingrette F., Renier G. The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf) 2006, 64:366-370.
13. Yavuz D., Deyneli O., Akpinar I., et al. Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. Eur J Endocrinol 2003, 149:187-193.
14. Limas C.J., Kroupis C., Haidaroglou A., Cokkinos D.V. Hyperprolactinaemia in patients with heart failure: clinical and immunogenetic correlations. Eur J Clin Invest 2002, 32:74-78.
15. Wallaschofski H., Donne M., Eigenthaler M., et al. PRL as a novel potent cofactor for platelet aggregation. J Clin Endocrinol Metab 2001, 86:5912-5919.
16. Wallaschofski H., Lohmann T., Stumpf C., Daniel W.G., Garlichs C.D. Lack of relevant association between prolactin and immune responses in patients with chronic heart failure. Eur J Clin Invest 2003, 33:1018. [author reply 1019].
17. Atmaca A., Gurlek A., Dagdelen S., et al. Hyperprolactinemia of pregnancy is not associated with increased in vivo platelet activity and shortened in vitro bleeding times. Exp Clin Endocrinol Diabetes 2006, 114:188-191.
18. Georgiopoulos, Stamatelopoulos G.A., Lambrinoudaki K.S., et al. preclinical atherosclerosis in menopausal women with cardiovascular risk factors. Hypertension 2009, 54:98-105.
19. Zhang L., Curhan G.C., Forman J.P. Plasma prolactin level and risk of incident hypertension in postmenopausal women. J Hypertens 2010, 28:1400-1405.
20. Völzke H., Alte D., Schmidt C.O., et al. Cohort profile: the study of health in pomerania. Int J Epidemiol 2011, 40:294-307.
21. Haring R., Alte D., Volzke H., et al. Extended recruitment efforts minimize attrition but not necessarily bias. J Clin Epidemiol 2009, 62:252-260.
22. Molitch M.E. Drugs and prolactin. Pituitary 2008, 11:209-218.
23. Mancia G., De Backer G., Dominiczak A., et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007, 25:1105-1187.
24. Devereux R.B., Alonso D.R., Lutas E.M., et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986, 57:450-458.
25. Lang R.M., Bierig M., Devereux R.B., et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005, 18:1440-1463.
26. Lang R.M., Bierig M., Devereux R.B., et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006, 7:79-108.
27. Völzke H., Schwahn C., Hummel A., et al. Tooth loss is independently associated with the risk of acquired aortic valve sclerosis. Am Heart J 2005, 150:1198-1203.
28. Haring R., Baumeister S.E., Völzke H., et al. Prospective association of low total testosterone concentrations with an adverse lipid profile and increased incident dyslipidemia. Eur J Cardiovasc Prev Rehabil 2011, 18:86-96.
29. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004, 159:702-706.
30. Lieb W., Xanthakis V., Sullivan L.M., et al. Longitudinal tracking of left ventricular mass over the adult life course: clinical correlates of short- and long-term change in the framingham offspring study. Circulation 2009, 119:3085-3092.
31. Tasevska-Dinevska G., Kennedy L.M., Cline-Iwarson A., Cline C., Erhardt L., Willenheimer R. Gender differences in variables related to B-natriuretic peptide, left ventricular ejection fraction and mass, and peak oxygen consumption, in patients with heart failure. Int J Cardiol 2011, 149:364-371.
32. Corona G., Mannucci E., Jannini E.A., et al. Hypoprolactinemia: a new clinical syndrome in patients with sexual dysfunction. J Sex Med 2009, 6:1457-1466.
33. Corona G., Rastrelli G., Boddi V., et al. Prolactin levels independently predict major cardiovascular events in patients with erectile dysfunction. Int J Androl 2010, 33:1-8.
34. Hilfiker-Kleiner D., Kaminski K., Podewski E., et al. A cathepsin D-cleaved 16kDa form of prolactin mediates postpartum cardiomyopathy. Cell 2007, 128:589-600.
35. Yamac H., Bultmann I., Sliwa K., Hilfiker-Kleiner D. Prolactin: a new therapeutic target in peripartum cardiomyopathy. Heart (British Cardiac Society) 2010, 96:1352-1357.
36. van Zaane B., Reuwer A.Q., Buller H.R., Kastelein J.J., Gerdes V.E., Twickler M.T. Hormones and cardiovascular disease: a shift in paradigm with clinical consequences?. Semin Thromb Hemost 2009, 35:478-487.
37. Sauro M.D., Bing B., Zorn N.E. Prolactin induces growth-related gene expression in rat aortic smooth muscle in vivo. Eur J Pharmacol 1992, 225:351-354.
38. Sauro M.D., Zorn N.E. Prolactin induces proliferation of vascular smooth muscle cells through a protein kinase C-dependent mechanism. J Cell Physiol 1991, 148:133-138.
39. Molinari C., Grossini E., Mary D.A., et al. Prolactin induces regional vasoconstriction through the beta2-adrenergic and nitric oxide mechanisms. Endocrinology 2007, 148:4080-4090.
40. Cataldo L., Chen N.Y., Yuan Q., et al. Inhibition of oncogene STAT3 phosphorylation by a prolactin antagonist, hPRL-G129R, in T-47D human breast cancer cells. Int J Oncol 2000, 17:1179-1185.
41. Hilfiker-Kleiner D., Hilfiker A., Drexler H. Many good reasons to have STAT3 in the heart. Pharmacol Ther 2005, 107:131-137.
42. Hilfiker-Kleiner D., Hilfiker A., Fuchs M., et al. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ Res 2004, 95:187-195.
43. Corbacho A.M., Martinez De La Escalera G., Clapp C. Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis. J Endocrinol 2002, 173:219-238.
44. Selle T., Renger I., Labidi S., Bultmann I., Hilfiker-Kleiner D. Reviewing peripartum cardiomyopathy: current state of knowledge. Future Cardiol 2009, 5:175-189.
45. Katznelson L., Riskind P.N., Saxe V.C., Klibanski A. Prolactin pulsatile characteristics in postmenopausal women. J Clin Endocrinol metab 1998, 83:761-764.
46. Davis C.E., Rifkind B.M., Brenner H., Gordon D.J. A single cholesterol measurement underestimates the risk of coronary heart disease. An empirical example from the Lipid Research Clinics Mortality Follow-up Study. JAMA 1990, 264:3044-3046.